肿瘤学前沿(Frontiers In Oncology)是一本由Frontiers Media S.A.出版的一本Biochemistry, Genetics and Molecular Biology-Cancer Research学术刊物,主要报道Biochemistry, Genetics and Molecular Biology-Cancer Research相关领域研究成果与实践。本刊已入选来源期刊,该刊创刊于2011年,出版周期1 issue/year。2021-2022年最...
2个细分领域MEDICINE, RESEARCH & EXPERIMENTAL和ONCOLOGY内位列Q1区,在MEDICINE, RESEARCH & EXPERIMENTAL 中排名20/136;在ONCOLOGY中排名39/241。 影响因子(Impact Factor), 简称IF,是科睿唯安(Clariate Analytics)发布的期刊引证报告(Journal Citation Reports,JCR®)中的一项数据,即某期刊在期刊引证报告年份(JCR ...
affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Up to date, 5 products have been launched in China, 1 has been approved for marketin...
3月20日,科睿唯安官方发布了2023年最新的SCI目录,目前共有SCIE期刊9509本,其中有35本期刊突然被剔除。包括影响因子高达7.31的Oxidative Medicine and Cellular Longevity和很多科研硕博耳熟能详的Journal of Oncology,大家在之后的投稿中,需要注意: 1.Advances m Materials Science and Engineering 2.098 2. Annals of ...
Frontiers in Oncology杂志的主编是美国康奈尔大学威尔康奈尔医学院迈耶癌症中心的Giuseppe Giaccone教授,一位已经合作发表了500多篇论文的大佬级学者。Giaccone教授主攻肺癌、胸腺恶性肿瘤等领域,致力于研究新的化学疗法和新的抗癌治疗策略,尤其是针对癌细胞的靶向药物。 早在2012年之前,Giaccone教授 +11 分享回复1 ...
To make radiogenomic biomarkers reliable in oncology, standardization of assay criteria, image capture, segmentation, trial design, and analytical methods is imperative. Along with this, a focus on creating an extensive imaging database inclusive of genomic profiles, demographics, treatment details, and...
documents published in that journal. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) ...
(unpaid); consultant and speaker honorarium, Boston Scientific US, 2019; institutional principal investigator for clinical trials sponsored by Celgene, Novocure, Intima Biosciences, and the National Cancer Institute; and University of Minnesota membership in the Caris Life Sciences Precision Oncology ...
services, from IRB-approved tissue preservation to standard IVF. Since the inception of the Oncofertility Network, there has been a dramatic increase in oncology patients seeking fertility preservation options, with the highest number in 2020. SASREG provides accreditation to clinics that maintain a ...
2023 ASCO (American Society of Clinical Oncology) meeting, BeiGene reported the latest results from the Phase II ROSEWOOD study, evaluating the combination of Zanubrutinib and obinutuzumab in heavily pretreated R/R FL patients. The ROSEWOOD study is a randomized, open-label Phase II clinical ...